Skip to main content
S&P 5007,810.71+0.58%DOW51,658.02+0.83%NASDAQ27,344.67+0.56%BTC$82,668.00+2.47%ETH$2,486.18+2.91%GOLD$4,219.30+1.50%OIL$91.75+0.28%
Smart Investors Daily
SID Premium
PU

NASDAQ · PULM

Pulmatrix, Inc.

Healthcare · Biotechnology

$1.53

Down-$0.06 (-3.74%)

Updated Oct 9, 2026, 6:04 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
14.43M
P/E ratio
-2.32
Dividend yield
0.00%
52-week range
$1.16 – $2.49
Volume
13.14K
Avg. volume
11.96K

Price performance · PULM

PULM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

PULM closed at $1.53 after 21 trading sessions, up 4.60% for the selected period.

Last close
$1.53
Period change
+4.60%
Period low
$1.40
Period high
$1.70
Daily close
View OHLC price history
PULM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$1.45$1.58$1.4201$1.527113.14K
Oct 7, 2026$1.46$1.51$1.43$1.4911.88K
Oct 6, 2026$1.50$1.5799$1.41$1.4319.47K
Oct 5, 2026$1.55$1.59$1.4514$1.4824.31K
Oct 2, 2026$1.59$1.5987$1.48$1.5715.27K
Oct 1, 2026$1.54$1.55$1.4972$1.547.94K
Sep 30, 2026$1.54$1.58$1.5002$1.528.45K
Sep 29, 2026$1.59$1.63$1.5554$1.5577.4K
Sep 28, 2026$1.68$1.68$1.5433$1.5940.18K
Sep 25, 2026$1.64$1.6968$1.60$1.6112.35K
Sep 24, 2026$1.685$1.72$1.66$1.6714.31K
Sep 23, 2026$1.72$1.755$1.65$1.68529.67K
Sep 22, 2026$1.77$1.7761$1.645$1.70113.24K
Sep 21, 2026$1.39$1.68$1.39$1.68259.33K
Sep 18, 2026$1.40$1.46$1.38$1.4423.2K
Sep 17, 2026$1.40$1.4329$1.38$1.432914.41K
Sep 16, 2026$1.44$1.4401$1.3824$1.4017.09K
Sep 15, 2026$1.425$1.445$1.4102$1.4453.41K
Sep 14, 2026$1.39$1.47$1.39$1.457.52K
Sep 11, 2026$1.44$1.46$1.41$1.417.27K
Sep 10, 2026$1.51$1.51$1.3999$1.4624.54K

Latest PULM news

The latest Smart Investors Daily articles mentioning PULM.

Stock researchCompany · Overview

PULM research

Overview

Company profile and research snapshot.

Company profile

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PULM recent ratings
DateFirmRatingTarget
Aug 15, 2023HC Wainwright & Co.Buy—
May 15, 2023HC Wainwright & Co.Buy—
Feb 7, 2023HC Wainwright & Co.Buy—
Mar 30, 2022HC Wainwright & Co.Buy—
Apr 13, 2021HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria

Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicineEos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesityEos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing first-in-class mitochondrial-tar

Benzinga · Aug 13, 2026

Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY

Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By